TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting with STEMI~2. Informed, written consent~Exclusion Criteria:~1. Age \< 18 years or Age \> 90 years~2. Active bleeding; bleeding diathesis; coagulopathy~3. Increased risk of bradycardic events~4. History of gastrointestinal or genitourinary bleeding \<2 months~5. Major surgery in the last 6 weeks~6. History of intracranial bleeding or structural abnormalities~7. Suspected aortic dissection~8. Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, unconsciousness, known malignancies or other comorbid conditions with life expectancy \<1 year)~9. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.~10. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows~11. Known relevant hematological deviations: Hb \<10 g/dl, PLT\<100x10\^9/l~12. Use of coumadin derivatives within the last 7 days~13. Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine~14. Known severe liver disease, severe renal failure~15. Known allergy to the study medications~16. Pregnancy~17. Human immunodeficiency virus treatment~18. The use of IIBIIIA receptor antagonists in the 48 hours before enrollment (if abciximab use then in the last 14 days).~19. If the patients cannot sign percutaneous coronary intervention (PCI) informed consent for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Oral Ticagrelor (Type: ACTIVE_COMPARATOR): None
- Chewing Ticagrelor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have disease progression/relapse while on full-dose imatinib, or are intolerant of any dose of imatinib.~* At least 3 months post stem cell transplantation~* Able to take daily oral capsules/tablets reliably~Exclusion Criteria:~* Subjects with Philadelphia chromosome, and bcr-abl negative CML~* Overt leptomeningeal leukemia~* Subjects without evidence of leukemia in bone marrow (extramedullary disease only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SKI-606 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate-Inadequate Response Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects who are considered methotrexate inadequate responders~* 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count)~Exclusion Criteria:~* Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies~* Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous)~* Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules)~* Subjects with severe chronic or recurrent bacterial infections~* Subjects who have received treatment with rituximab~An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Abatacept (Type: ACTIVE_COMPARATOR): Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
- Intravenous (IV) Abatacept (Type: ACTIVE_COMPARATOR): Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> or = 18, able to provide informed consent~2. Body-mass index greater than or equal to 25~3. Presence of at least one indicator of insulin resistance from the following list:~   * Family history of Type 2 diabetes (parent, sibling)~  * Fasting glucose 100 - 125 mg/dl~  * Fasting serum insulin greater than or equal to 7uU/ml~  * Personal history of gestational diabetes~4. Negative pregnancy test for women with childbearing potential~Exclusion Criteria:~1. Diagnosis of diabetes mellitus Type 1 or Type 2~2. Active autoimmune disease, chronic infection, current malignancy (excluding basal cell carcinoma), or other active inflammatory state that, in the opinion of the investigators, would affect insulin sensitivity~3. Oral corticosteroid use in prior six months, or expectation of needing corticosteroid therapy in upcoming six months~4. Known allergy or intolerance to HCQ~5. Known glucose-6 phosphate dehydrogenase deficiency~6. Known eye disease associated with retinal pigmentation abnormalities~7. Known diabetic retinopathy requiring past or planned laser therapy~8. Inability to comply with visit schedule and protocol requirements~9. Inability to manage and take medication as instructed~10. Current or planned pregnancy in upcoming 12 months~11. Inability or unwillingness to use reliable method of contraception (for women of childbearing years, men, or men's partners with childbearing potential), such as oral contraceptive pills, barrier method (diaphragm and condom with spermicide), intrauterine device, or depo-provera injections for 3 months prior to enrollment~12. Anemia (HGB \< 9)~13. Any history of bariatric (weight loss) surgery~14. Current use of the medication Glucophage (metformin)~15. Weight changes of 6 pounds or more in the past 4 weeks~16. Any other underlying or concomitant condition, which in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- hydroxychloroquine (Type: EXPERIMENTAL): Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
- Placebo (Type: PLACEBO_COMPARATOR): Thirteen weeks of daily placebo following FSIGTT testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with histopathologic diagnosis of well-differentiated neuroendocrine tumour or carcinoma according to WHO classification~* patients who, according to RECIST criteria (Response Evaluation Criteria in Solid Tumours) present measurable disease~* patients with progressive disease in the previous 6 months before their inclusion in the study~* patients with positive IN111 octreotide scintigraphy~Exclusion Criteria:~* patients with surgically removable localised disease~* patients with progressive disease in the first six months of being diagnosed~* patients with intestinal obstruction due to a carcinoid tumour~* patients who have received treatment with somatostatin analogues during the 6 months before being included in the study~* patients who have received treatment with radiotherapy, chemotherapy or interferon 4 weeks before being included in the study, or planned to receive these during the study~* patients who have received treatment with liver artery embolisation or radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study, or planned during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age at time of enrollment 28 0/7 to 35 6/7 weeks postmenstrual age~* Age less than or equal to 36 hours old~* On nCPAP 6 with supplemental oxygen requirement (Fi02 greater than or equal to 30%) for greater than or equal to 30 minutes (to maintain Sa02 between 88-92%)~* Chest radiograph and clinical presentation consistent with respiratory distress syndrome (tachypnea, retractions, nasal flaring, and/or grunting~Exclusion Criteria:~* Prior mechanical ventilation or surfactant administration~* Major congenital anomaly~* Abnormality of the airway~* Respiratory distress secondary to an etiology other than respiratory distress syndrome (pneumothorax, meconium aspiration syndrome, pneumonia, hypoxic-ischemic encephalopathy)~* Apgar score \< 5 at 5 minutes of age

- Gender: ALL
- Minimum Age: None
- Maximum Age: 36 Hours
- Healthy Volunteers: f

Study Arms:
- nCPAP Control Group (Type: ACTIVE_COMPARATOR): Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
- LMA Group (Type: EXPERIMENTAL): Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma within transplantation criteria~Exclusion Criteria:~* Disseminated disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of erectile dysfunction (ED), International Index of Erectile Function (IIEF) score \>=21 at screening and baseline, and receiving treatment with a stable regimen of a phosphodiesterase 5 (PDE 5) inhibitor (ie, sildenafil, vardenafil, or tadalafil) for the treatment of ED for at least 3 months before screening~* Study participant in a stable, monogamous sexual relationship with the same woman for at least 6 months before screening and plan to maintain this relationship for the duration of the study~* Study participant medically stable (ie, in good general health) on the basis of physical examination, medical history, vital signs, 12 lead ECG, and clinical laboratory tests performed at screening~Exclusion Criteria:~* History suggestive of syncope (a condition characterized by a loss of consciousness)~* History of medical events such as surgical interventions or neurologic conditions (eg, multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE~* Current major psychiatric disorder such as mood disorder, anxiety disorder, schizophrenia, mania, suicidal ideation, other psychotic disorder, or alcoholism~* Known allergy, hypersensitivity, or intolerance to selective serotonin reuptake inhibitors (SSRIs) or selective noradrenaline reuptake inhibitors (SNRIs)~* Taken another investigational drug (or vaccine) within 30 days or used an investigational medical device within 6 months before screening, or enrolled in another investigational study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapoxetine + PDE5I (Type: EXPERIMENTAL): Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
- Placebo + PDE5I (Type: PLACEBO_COMPARATOR): Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults, male or female, aged 5 to 55 years, inclusive, who have provided written informed consent.~* New or relapsed VL or prior VL treatment failure on a regimen not containing Paromomycin or AmBisome®. The diagnosis of VL must be confirmed by a parasite-positive splenic aspirate.~Exclusion Criteria:~* LFT greater than 3 times ULN ( AST, ALT, S.Bilirubin, Alkaline Phosphatase, Hb \< 4 gm/dl.~* Platelet \<40,000/ mm3~* Prothrombin Time \> 3 Sec. longer than Control.~* Creatinine \> 3 times~  * Normal Value For Male ( 0.6 to 1.1)~ * Normal Value For Female ( 0.5 to 0.9)~* Absolute Leucocyte count- \< 1,000~* HIV infection~* Abnormal audiometric and/or vestibular dysfunction~* History of renal dysfunction~* Other severe medical conditions~* History of allergy or hypersensitivity to aminoglycosides~* Treatment with a parenteral aminoglycoside within 28 days prior to randomisation~* Previous VL treatment within the past 14 days~* Previous treatment for VL with paromomycin at any time~* Pregnancy, lactation, or lack of use of contraception in women of childbearing potential

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Paromomycin for 21 days @ 11mg/kg
- 1 (Type: EXPERIMENTAL): Paromomycin for 14 days @ 11mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria. Subjects must meet all relevant criteria to participate.~1. (a) Former premature (\< 30 weeks' gestation at birth), ELBW (\<1001 grams' birth weight) infant, 6 months, 0 days - 17 months, 31 days of age., OR (b) Former full term (37-42 weeks' gestation at birth), normal birth weight (\>2500 grams' birth weight) infant, 6 months, 0 days - 17 months, 31 days of age.~2. No prior influenza immunization.~3. Eligible for influenza immunization.~4. Parental permission.~5. Agreement of primary care provider.~6. Parents likely to be able to comply with study visits.~Exclusion criteria. Subjects may not participate if they meet any one of these criteria.~1. Known immunodeficiency.~2. Systemic corticosteroid administration at time of study enrollment.~3. Requiring supplemental oxygen.~4. Contraindication to influenza immunization (e.g. egg allergy).~5. Physician-diagnosed influenza illness in the current influenza season.~6. Any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the subject.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Premature infants
- 2 (Type: None): Full term infants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion (requires all):~* New diagnosis of AASV (WG or MPA) (within the previous six months)~* Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1)~* ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix )~* Written informed consent~Exclusion Criteria:~* Previous treatment with:~  * MMF: more than two weeks ever.~ * Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg)~ * Rituximab or high dose intravenous immunoglobulin within the last twelve months~* Active infection (including hepatitis B, C, HIV and tuberculosis).~* Known hypersensitivity to MMF, AZA or CYC.~* Cancer or an individual history of cancer (other than resected basal cell skin carcinoma).~* Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.~* Any condition judged by the investigator that would cause the study to be detrimental to the patient.~* Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mycophenolate mofetil (Type: EXPERIMENTAL): Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
- cyclophosphamide (Type: ACTIVE_COMPARATOR): pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* De novo patients with cervical dystonia~* Outpatient~* Patients to be of age 18 years or older~* Written informed consent to participate in the study~Exclusion Criteria:~* Pre-treatment of cervical dystonia with botulinum toxin~* Pre-treatment with botulinum toxin for any indication other than cervical dystonia within the past 12 months~* Pure retro- or antecollis~* Neurological or other diseases which may affect head and neck motor function or neuromuscular transmission, e.g. polyneuropathy with pareses, myasthenia, myopathy, motor neurone diseases, Bekhterev's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete